The 2016/17 influenza season in Europe is marked by the predominant circulation of influenza A(H3N2) viruses \[[@r1]\], with significant pressure on hospitals, mostly due to patients aged 65 years and older developing severe disease \[[@r1]\]. Many European countries have reported excess all-cause mortality \[[@r2]\]. Initial estimates based on Swedish and Finnish electronic databases suggest low influenza vaccine effectiveness (IVE) among older adults \[[@r3],[@r4]\]. We measured early IVE at primary care and hospital levels against laboratory-confirmed influenza A(H3N2) in Europe.

Primary care and hospital-based multicentre case control studies in Europe to measure influenza vaccine effectiveness
=====================================================================================================================

We conducted separate multicentre primary care and hospital-based case--control studies and analyses using the test-negative design (TND). We have described the methods in detail previously \[[@r5]-[@r7]\].

In the primary care study, comprising 893 practitioners (including general practitioners and paediatricians) in 12 countries, we included a systematic sample of all community-dwelling patients presenting to their practitioner with influenza-like illness (ILI), as defined by the European Union ILI case definition (*sudden onset* of symptoms and at least one of the following systemic symptoms: fever or feverishness, malaise, headache, myalgia, and at least one of the following respiratory symptoms: cough, sore throat, shortness of breath). In the hospital study, comprising 27 hospitals from 11 countries, we included community-dwelling patients aged 65 years and older admitted to hospital for influenza-related clinical conditions with symptoms compatible with severe acute respiratory infection (SARI). Each study site adapted a generic protocol to their local setting \[[@r8],[@r9]\].

At each study site, the study period commenced more than 14 days after the start of the vaccination campaign and lasted from the week of the first influenza case to the date of sending data for the interim analysis at the end of January 2017.

A case of confirmed influenza was an ILI (primary care) or SARI (hospital) patient who was swabbed and tested positive for influenza A(H3N2) virus using real-time RT-PCR. Controls were ILI (primary care) or SARI (hospital) patients who tested negative for any influenza virus using RT-PCR.

We excluded patients with contraindications for influenza vaccination, SARI patients discharged from a previous hospital stay within 48 hours of symptom onset (hospital), those with a previous laboratory-confirmed influenza in the season, those refusing to participate or unable to consent, those who had received antiviral drugs before swabbing (primary care), those swabbed more than 7 days after symptom onset, patients with missing laboratory results and any patients positive to any influenza virus other than influenza A(H3N2).

Practitioners and hospital teams collected clinical and epidemiological information including date of symptom onset and date of swabbing, 2016/17 seasonal vaccination status, date of vaccination and vaccine product administered, 2015/16 seasonal vaccination status, sex, age, presence of chronic conditions, whether the patient belonged to a target group for influenza vaccination (primary care) and number of hospitalisations for chronic conditions in the past 12 months.

We defined individuals as vaccinated if they had received at least one dose of the 2016/17 influenza vaccine at least 15 days before ILI/SARI symptom onset. We excluded individuals vaccinated less than 15 days before symptom onset and individuals with unknown vaccination date.

At primary care level, nine study sites (France, Germany, Hungary, Ireland, the Netherlands, Portugal, Romania, Spain and Sweden) participated in a sub-study using an in-depth laboratory protocol, and randomly selected positive influenza A(H3N2) specimens for genetic sequencing.

We pooled individual patient data in each study and computed the pooled IVE as ((1−OR of vaccination between cases and controls) × 100) using logistic regression with study site as a fixed effect. We conducted a complete case analysis excluding patients with missing values for any of the variables in the model. All IVE estimates were adjusted for study site, calendar time of onset and age (where sample size allowed). Further potential confounding factors included sex, underlying chronic conditions and hospitalisations in the past year.

We stratified IVE by age group. We measured IVE among the target groups for influenza vaccination at primary care level, defined as older adults (aged over 54, 59 or 64 years depending on study site), individuals with chronic conditions and other groups for whom the vaccine was recommended in a given country (e.g. pregnant women, healthcare workers and other professional groups, depending on the study site).

Influenza vaccine effectiveness in primary care
===============================================

In the primary care analysis, we included 2,250 cases of influenza A(H3N2) and 2,773 negative controls.

The 2016/17 seasonal influenza vaccine coverage was 10.3% among influenza A(H3N2) cases and 10.9% among controls. Compared with cases, a greater proportion of controls belonged to the age group of 0--4-year-olds (26.1% vs 12.3%) and a lower proportion belonged to the age group of 5--14-year-olds (12.1% vs 22.7%) ([Table 1](#t1){ref-type="table"}).

###### Influenza A(H3N2) cases and controls included in the 2016/17 season influenza vaccine effectiveness analysis, I-MOVE/I-MOVE+ multicentre case control studies (primary care (n = 5,023) and hospital (n = 635) levels) Europe, influenza season 2016/17

  Variables                                                                       Primary care level   Hospital level                                                                  
  ------------------------------------------------------------------------------- -------------------- ---------------- ------ ------- ------- ------ ----- ----- ------- ------ ----- -------
  Median age (years)                                                              29                   28               79     80                                                      
  **Age groups (years)**                                                                                                                                                               
  0--4                                                                            276                  2,242            12.3   723     2,766   26.1   NA    NA                         
  5--14                                                                           508                  2,242            22.7   336     2,766   12.1   NA    NA                         
  15--64                                                                          1,177                2,242            52.5   1,438   2,766   52.0   NA    NA                         
  65--79                                                                          234                  2,242            10.4   214     2,766   7.7    138   267   51.7    185    368   50.3
  ≥ 80                                                                            47                   2,242            2.1    55      2,766   2.0    129   267   48.3    183    368   49.7
  Missing                                                                         8                                     7              0              0                                
  **Sex**                                                                                                                                                                              
  Female                                                                          1,126                2,237            50.3   1,407   2,758   51.0   141   267   52.8    190    368   51.6
  Missing                                                                         13                                    15             0              0                                
  Chronic conditions                                                                                                                                                                   
  At least one chronic condition                                                  451                  2,237            20.2   542     2,743   19.8   237   255   92.9    321    344   93.3
  Missing                                                                         13                                    30             12             24                               
  At least one hospitalisation in the previous 12 months for chronic conditions   26                   2,196            1.2    57      2,686   2.1    66    247   26.7    146    334   43.7
  Missing                                                                         54                                    87             20             34                               
  **Target group for vaccination**                                                                                                                                                     
  Belongs to a target group for vaccination                                       616                  2,241            27.5   706     2,755   25.6   267   267   100.0   368    368   100.0
  Missing                                                                         9                                     18             0              0                                
  **Swab delay**                                                                                                                                                                       
  Swabbed within 3 days of symptom onset                                          2,024                2,250            90.0   2,291   2,773   82.6   154   267   57.7    212    368   57.6
  **Vaccination status**                                                                                                                                                               
  Seasonal flu vaccination 16--17                                                 231                  2,250            10.3   301     2,773   10.9   108   267   40.4    191    368   51.9
  Seasonal flu vaccination 15--16                                                 223                  2,196            10.2   316     2,665   11.9   117   252   46.4    199    362   55.0
  Missing                                                                         54                                    108            15             6                                
  **Previous and current season influenza vaccination**                                                                                                                                
  Not vaccinated in any season                                                    1,929                2,196            87.8   2,284   2,665   85.7   128   252   50.8    147    362   40.6
  Current season vaccination only                                                 44                   2,196            2.0    65      2,665   2.4    7     252   2.8     16     362   4.4
  Previous season vaccination only                                                43                   2,196            2.0    95      2,665   3.6    20    252   7.9     28     362   7.7
  Current and previous season vaccination                                         180                  2,196            8.2    221     2,665   8.3    97    252   38.5    171    362   47.2
  Missing                                                                         54                                    108            15             6                                
  **Type of vaccine**                                                                                                                                                                  
  Not vaccinated                                                                  2019                 2,215            91.2   2,472   2,725   90.7   159   261   60.9    177    359   49.3
  Inactivated subunit egg                                                         97                   2,215            4.4    108     2,725   4.0    65    261   24.9    101    359   28.1
  Inactivated split virion egg                                                    71                   2,215            3.2    118     2,725   4.3    32    261   12.3    74     359   20.6
  Adjuvanted                                                                      18                   2,215            0.8    21      2,725   0.8    5     261   1.9     7      359   1.9
  Quadrivalent vaccine                                                            10                   2,215            0.5    6       2,725   0.2    0     261   0.0     0      359   0.0
  Missing vaccine type                                                            35                                    48             6              9                                
  **Month of onset**                                                                                                                                                                   
  October 2016                                                                    4                    2,250            0.2    84      2,773   3.0    0     267   0.0     0      368   0.0
  November 2016                                                                   154                  2,250            6.8    759     2,773   27.4   3     267   1.1     6      368   1.6
  December 2016                                                                   1,199                2,250            53.3   1,194   2,773   43.1   174   267   65.2    236    368   64.1
  January 2017                                                                    893                  2,250            39.7   736     2,773   26.5   90    267   33.7    126    368   34.2
  **Study sites**                                                                                                                                                                      
  Croatia                                                                         13                   2,250            0.6    13      2,773   0.5    NA    NA                         
  Finland                                                                         NA                   NA               14     267     5.2     17     368   4.6                        
  France                                                                          584                  2,250            26.0   609     2,773   22.0   35    267   13.1    116    368   31.5
  Germany                                                                         28                   2,250            12.8   873     2,773   31.5   NA    NA                         
  Hungary                                                                         39                   2,250            1.7    84      2,773   3.0    NA    NA                         
  Ireland                                                                         135                  2,250            6.0    113     2,773   4.1    NA    NA                         
  Italy                                                                           411                  2,250            18.3   367     2,773   13.2   37    267   13.9    58\)   368   15.8
  Lithuania                                                                       NA                   NA               30     267     11.2    18     368   4.9                        
  Navarra                                                                         NA                   NA               20     267     7.5     34     368   9.2                        
  The Netherlands                                                                 47                   2,250            2.1    142     2,773   5.1    6     267   2.2     19     368   5.2
  Poland                                                                          9                    2,250            0.4    33      2,773   1.2    NA    NA                         
  Portugal                                                                        156                  2,250            6.9    80      2,773   2.9    36    267   13.5    14     368   3.8
  Romania                                                                         27                   2,250            1.2    9       2,773   0.3    60    267   22.5    37     368   10.1
  Spain                                                                           474                  2,250            21.1   303     2,773   10.9   29    267   10.9    55     368   14.9
  Sweden                                                                          66                   2,250            2.9    147     2,773   5.3    NA    NA                         

NA: Not applicable.

Nine study sites sequenced 204 randomly selected specimens out of 1,817 (11.2%) ([Table 2](#t2){ref-type="table"}). Of these, 156 (76.5%) belonged to the 3C.2a1 clade A/Bolzano/7/2016, 46 (22.5%) to A/Hong Kong/4801/2014 (3C.2a) and two (1.0%) to A/Switzerland/9715293/2013 (3C.3a).

###### Influenza A(H3N2) viruses characterised by clade, amino acid substitutions and study site, at nine participating laboratories, I-MOVE/I-MOVE+ primary care multicentre case control study, Europe, influenza season 2016/17 (n = 1,817)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characterised viruses (clade)        Germany\   France\   Hungary\   Ireland\   The Netherlands\   Portugal\   Romania\   Spain\    Sweden\   Total\                                                       
                                       n = 289    n = 584   n = 39     n = 135    n = 47             n = 156     n = 27     n = 474   n = 66    n = 1,817                                                    
  ------------------------------------ ---------- --------- ---------- ---------- ------------------ ----------- ---------- --------- --------- ----------- ----- ---- ----- ---- ----- ---- ---- ---- ----- ----
  A/HongKong/4801/2014 (3C.2a)         10         6         3          0          8                  8           4          3         4         46                                                           

  N121K + S144K                        3          30        6          100        3                  100         0          1         12        8           100   4    100   3    100   3    75   31   67    

  A/Bolzano/7/2016 (3C.2a1)            33         19        3          5          20                 23          8          36        9         156                                                          

  N171K + N121K + I140M                10         30        0          0          0                  7           35         2         9         4           50    8    22    3    33    34   22              

  N171K + N121K + T135K                2          6         0          2          67                 0           3          15        0         0           1     3    3     33   11    7                    

  N171K + N121K + K92R + H311Q         8          24        0          1          33                 1           20         4         20        4           17    0    10    28   0     28   18              

  N171K + R142G                        7          21        3          16         0                  3           60         3         15        17          74    0    1     3    1     11   35   22         

  A/Switzerland/9715293/2013 (3C.3a)   0          0         0          2          0                  0           0          0         0         2                                                            

  Total sequenced/total A(H3N2)        43         15        25         4          6                  15          7          5         28        60          31    20   12    44   39    8    13   20   204   11
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Among the 156 viruses of the 3C.2a1 clade, further genetic groups have emerged in 108 (69.2%) ([Table 2](#t2){ref-type="table"}). These include 34 viruses in group 1 (22%), harbouring the I140M substitution located in the antigenic site A of the haemagglutinin, in addition to changes in amino acid positions 171 and 121, both located in the antigenic site D. Eleven viruses belonged to group 2 (7%), carrying the T135K mutation located in the antigenic site A and resulting in the loss of a glycosylation site, in addition to the already mentioned changes in positions 171 and 121. Twenty-eight viruses belonged to genetic group 3 (18%), carrying the K92R and H311Q substitutions located in the antigenic sites E and C, respectively, in addition to changes in positions 171 and 121. Finally, 35 viruses belonged to group 4 (22%), carrying the R142G mutation located in the antigenic site A and the N171K substitution. Thirty-one viruses (67%) belonging to the 3C.2a clade (A/HongKong/4801/2014) carried the substitutions N121K and S144K, the latter located in the antigenic site position A.

Adjusted IVE against influenza A(H3N2) across all age groups was 38.0% (95% CI: 21.3 to 51.2). It was 44.1% (95% CI: −12.3 to 72.2), 46.9% (95% CI: 25.2 to 62.3) and 23.4% (95% CI: −15.4 to 49.1) in 0--14, 15--64 and ≥ 65 year-olds, respectively. The IVE in the target group for vaccination was 25.7% (95% CI: 1.5 to 43.9) ([Table 3](#t3){ref-type="table"}).

###### Pooled adjusted seasonal vaccine effectiveness against laboratory-confirmed influenza A(H3N2) by age group and target group for vaccination, I-MOVE/I-MOVE+ multicentre case control studies (primary care (n = 4,937) and hospital (n = 635)), influenza season 2016/17

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analyses                                                                                                                                                     Adjustment / stratification   Cases   Controls   Adjusted VE   95% CI                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------- ------- ---------- ------------- -------- ----- ------ ------------------ ---------------
  Primary care                                                                                                                                                                                                                                                         

  All ages\                                                                                                                                                    Adjusted by study site only   2,216   229        10            2,721    297   11     10.9               −8.3 to 26.6
  \                                                                                                                                                                                                                                                                    
  \                                                                                                                                                                                                                                                                    

  Adjusted by calendar time and study site                                                                                                                     2,216                         229     10         2,721         297      11    27.9   11.9 to 41.1       

  Adjusted by calendar time, age and study site                                                                                                                2,216                         229     10         2,721         297      11    38.4     22.2 to 51.3     

  Fully adjusted: calendar time, age, study site, presence of chronic conditions, sex                                                                          2,216                         229     10         2,721         297      11    38.0   21.3 to 51.2       

  By age group (years)^a^\                                                                                                                                     0--14                         773     20         3             1,043    27    3      44.1               −12.3 to 72.2
  \                                                                                                                                                                                                                                                                    

  15--64                                                                                                                                                       1,164                         69      6          1,410         126      9     46.9   25.2 to 62.3       

  ≥ 65                                                                                                                                                         278                           140     50         268           144      54    23.4   −15.4 to 49.1      

  Target group for vaccination^a^                                                                                                                              All ages                      606     201        33            698      235   34     25.7               1.5 to 43.9

  Hospital                                                                                                                                                                                                                                                             

  ≥ 65 years\                                                                                                                                                  Adjusted by study site only   267     108        40            368      191   52     −0.7               −46.8 to 30.9
  \                                                                                                                                                                                                                                                                    
  \                                                                                                                                                                                                                                                                    

  Adjusted by calendar time and study site                                                                                                                     267                           108     40         368           191      52    3      −42.2 to 33.8      

  Adjusted by calendar time, age and study site                                                                                                                267                           108     40         368           191      52    2.5    −43.6 to 33.8      

  Fully adjusted: time, age, study site, sex, chronic condition (lung, heart, renal disease, diabetes, cancer, obesity) and hospitalisation in the past year   240                           95      40         316           162      51    2.0    −51.7 to 36.8      

  By age group (years)^b^\                                                                                                                                     65--79                        130     38         29            165      70    42     7.9                −67.3 to 49.3

  ≥ 80                                                                                                                                                         115                           59      51         167           102      61    2.4    −81.3 to 47.5      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; VE: vaccine effectiveness at hospital level.

^a^ Adjusted by study site, age, calendar time, presence of chronic conditions and sex.

^b^ Adjusted by calendar time, age and study site.

Influenza vaccine effectiveness at hospital level
=================================================

In the hospital study, we included 267 cases of influenza A(H3N2) and 368 negative controls.

The 2016/17 seasonal influenza vaccine coverage was 40.4% among influenza A(H3N2) cases and 51.9% among controls. A higher proportion of controls were vaccinated with inactivated split-virion vaccine group (20.6% vs 12.3%). A higher proportion of controls had been hospitalised for chronic conditions in the past twelve months (43.7% vs 26.7%) ([Table 1](#t1){ref-type="table"}).

Adjusted IVE against influenza A(H3N2) among those aged 65 years and older was 2.5% (95% CI: −43.6 to 33.8), it was 7.9% (95% CI: −67.3 to 49.3) among those aged 65 to 79 years and 2.4% (95% CI: −81.3 to 47.5) among those aged 80 years and older ([Table 3](#t3){ref-type="table"}).

Discussion
==========

In primary care, early estimates suggest moderate IVE against influenza A(H3N2) among 0--64-year-olds and low IVE in the target group for influenza vaccination. Among those aged 65 years and older, IVE was low at both primary care and hospital level, however precision was low.

Viruses of the 3C.2a1 clade (A/Bolzano/7/2016) predominated in the study sites participating in the laboratory protocol. Compared to the vaccine virus A/HongKong/4801/2014, they had the N171K substitution and in addition, most of them had the N121K substitution. This clade appears to be antigenically similar to the A(H3N2) vaccine component. However, our sequencing results suggest that this cluster is continuing to evolve: 70% of sequenced viruses had further mutations, forming clusters defined by new HA1 amino acid substitutions in antigenic sites, including antigenic site A. We did not measure IVE against A/Bolzano/7/2016 viruses, as estimates were not robust because of the small sample size.

The 2016/17 early primary care IVE estimate among all ages was 38% (95% CI: 21.3 to 51.2), similar to the early estimates from the Canadian Sentinel Practitioner Surveillance \[[@r10]\] and comparable to early estimates against influenza A(H3N2) in previous seasons: 43% (95% CI: -0.4 to 67.7) in 2011/12 and 41.9% (95% CI: −67.1 to 79.8) in 2012/13 \[[@r11],[@r12]\]. This season, we reached better precision thanks to a larger sample size.

The IVE estimates among those aged 65 years and older and target groups for vaccination were low and, despite low precision, reinforce the risk assessment from the European Centre for Disease Prevention and Control (ECDC), which suggests to consider administering antiviral drugs to populations vulnerable to severe influenza irrespective of vaccination status, in line with national and international recommendations \[[@r1]\].

These early results are included in the Global Influenza Vaccine Effectiveness (GIVE) report to contribute to the World Health Organization consultation and information meeting on the composition of influenza virus vaccines for use in the 2017/18 northern hemisphere influenza season \[[@r13]\].

Conclusion
==========

The early season estimates presented here corroborate the suboptimal performance of inactivated influenza vaccine against influenza A(H3N2) that the I-MOVE team and others have reported in the previous post-2009 pandemic seasons \[[@r14],[@r15]\].
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